In both control samples and samples from cases of multiple sclerosis, the B12 concentration in lumbar cerebrospinal fluid was correlated with the concentration in serum. There was no correlation between B12 concentration and total protein in cerebrospinal fluid.
In both control samples and samples from cases of multiple sclerosis, the B12 concentration in lumbar cerebrospinal fluid was correlated with the concentration in serum. There was no correlation between B12 concentration and total protein in cerebrospinal fluid.
A number of estimations of serum B12 were also made with Lactobacillus leichmannii, after extraction in the presence and absence of cyanide. These showed a difference between cases of multiple sclerosis and controls, one interpretation of which might be that the serum in multiple sclerosis contains an abnormally low concentration of hydroxocobalamin.
Several investigations have been made of the vitamin B12 concentration in body fluids in multiple sclerosis, but the results are completely conflicting. Sobotka, Christoff, and Baker (1958) and Sobotka, Baker, Frank, Maker, and Margulies (1960) , using Ochromonas malhamensis, found large increases in serum and cerebrospinal fluid B12 in about a third of their cases. On the other hand O'Connor, Davis, Langworthy, and Chow (1960) , using Lactobacillus leichmannii, reported that the serum B12 was low in multiple sclerosis, half of their patients having concentrations within the pernicious anaemia range, and Bauer and Heinrich (1961) , using Euglena gracilis, also reported very low serum values. Gjertsen and Schrumpf (1962) , using Euglena gracilis, found low values in cerebrospinal fluid. Grann and Glass (1961) , using Ochromonas malhamensis, found normal serum B12 concentrations in the majority of cases; three out of 21 cases had elevated concentrations, but two of these had been given parenteral B12: one case had a subnormal concentration. The majority of their patients had normal B12 absorption as estimated by hepatic uptake. Worm-Petersen (1962) , using Euglena gracilis, z strain, found no significant difference in cerebrospinal fluid and serum B12 concentrations Received for publication 2 June 1964. between cases of multiple sclerosis and controls. Kidd, Gould, and Thomas (1963) (Smith, 1961) . Since the present work was completed, Simpson (1964) , using Euglena gracilis, z strain, has reported no significant dif-ference between cerebrospinal fluid and serum B12 concentrations in multiple sclerosis and control values.
MATERIALS AND METHODS
Estimations of levels of vitamin B12 in serum and cerebrospinal fluid were made by a modification of the method of Hutner, Bach, and Ross (1956) with Euglena gracilis, z strain. The cerebrospinal fluid, which was not centrifuged, was usually assayed at a dilution of 1 in 6, though when the amount available was small, dilutions of 1 in 8 or 1 in 12 were used. Serum estimations with Lactobacillus leichmannii were made as described by Matthews (1962) ; each sample was divided into two parts, one of which was assayed after extraction by heating for 30 minutes with acetate buffer pH 4-6 containing 20 mg. NaCN per litre, and the other after extraction in the same way with buffer containing no cyanide.
The control group for serum B12 was made up of hospital in-patients and out-patients aged 18 to 75, none of whom were known to have any condition affecting the serum B12 concentration. The group of cases of multiple sclerosis was made up of patients aged 17 to 57, in all of whom the diagnosis was firmly established. If the patients had received B12, this was noted. Samples of lumbar cerebrospinal fluid were divided into three groups.
1 THE CONTROL GROUP In this, thecerebrospinal fluidprotein concentration was not more than 50 mg. per 100 ml. and the cell count, Pandy Nonne-Apelt and Lange tests were normal, though many of the patients had organic neurological lesions.
2 A 'PATHOLOGICAL' GROUP In this, the cerebrospinal fluid protein concentration ranged from 55 to 500 mg. per 100 ml. and the white cell count up to 500 per c. mm., and in many cases there were other abnormal findings; the patients suffered from a variety of neurological disorders.
SAMPLES FROM CASES OF MULTIPLE SCLEROSIS
In addition, a small number of samples of ventricular cerebrospinal fluid were examined. These came from patients with a variety of neurological disorders; the protein concentration ranged up to 20 mg. per 100 ml., Group and in some cases there were other abnormal findings. None of the patients providing cerebrospinal fluid in groups 1 and 2 or ventricular cerebrospinal fluid were known to have any condition affecting the serum B12 concentration.
STATISTICAL METHODS The distribution of B12 concentrations in serum and cerebrospinal fluid fits a logarithmic distribution better than a normal one, as Worm-Petersen (1962) points out, and Simpson (1964) has used the logarithms of the observations for all calculations. We have also done this in addition to making calculations on the usual arithmetical basis. In the majority of instances the logarithmic method made no essential difference to the results of significance tests, and in such cases the logarithmic results are omitted for the sake of clarity. When there was an appreciable difference, logarithmic results are given. The significance of differences between means was assessed by the t test.
RESULTS
The B12 concentrations obtained in serum and lumber cerebrospinal fluid are shown in Table I . The mean concentration in 'pathological' cerebrospinal fluid was significantly higher than that in the control group ((P< 005 > 0-02). In patients with multiple sclerosis, none of whom were known to have had B12, the mean serum B12 concentration was not significantly different from that in controls, but the mean concentration in cerebrospinal fluid was significantly lower (controls, mean of logs 133, S.E. 0 03; multiple sclerosis, mean of logs 1-18, S.E. 0-05; P<0-02>001) and all the values except one were in the lower part of the control range (Fig. 1) . In both control subjects and the cases of multiple sclerosis, there was a correlation between the 132 concentration in serum and cerebrospinal fluid (Figs.   2 and 3) . In controls the ratio Of 612 concentration in cerebrospinal fluid to serum concentration in paired samples was 5 6%, whereas in multiple sclerosis it was only 3-8 %. Six other cases of multiple sclerosis were known to have been given parenteral B12 within three months of the estimations. In these, (Fig. 4) . The difference is significant (P< 0 01 >0-001).
DISCUSSION
The published values for B12 concentration in lumbar cerebrospinal fluid vary very widely (e.g. Ross, 1950; Sobotka, Baker, and Frank, 1960; Bauer and Heinrich, 1961; Yavorkovsky and Mai, 1961; Gjersten and Schrumpf, 1962) but the control values we have found agree well with those of Herbert and Zalusky (1961) , Worm-Petersen (1962) , and Kidd, et al. (1963) . The finding of a correlation between B12 concentrations in serum and cerebrospinal fluid confirms the reports of Worm-Petersen (1962) and of Simpson (1964) . We also agree with these authors on the lack of correlation between B12 concentration and total protein in cerebrospinal fluid, though this conflicts with the report of Yavorkovsky and Mai (1961) . sclerosis) may reflect an increase in the permeability of the blood-brain barrier.
The present work has produced no evidence of major alterations in B12 in serum and cerebrospinal fluid in multiple sclerosis, but it does suggest that there are minor abnormalities. High values were only found when the patients were known to have received B12. Excluding these cases, the total serum B12 was found to be normal using two different assay organisms, and the cerebrospinal fluid concentrations were all within the control range, though the mean was significantly lower than in controls. The tendency for levels of B12 in cerebrospinal fluid to be reduced in multiple sclerosis contrasts with the tendency for it to be increased in the group of miscellaneous neurological disorders. The results suggest that at a given concentration of serum B12 the concentration of B12 in cerebrospinal fluid is slightly lower in multiple sclerosis than in controls. No explanation for this can be suggested without further investigation, and it is unlikely to be explained until the factors governing the concentration of B12 in cerebrospinal fluid are better understood. These probably include not only the concentration of B12 in serum, but the permeability of the bloodbrain barrier, the B12-binding capacity of the cerebrospinal fluid (Meyer, Bertcher, and Mulzac, 1959; Clausen and Munkner, 1962; Worm-Petersen, 1962) and perhaps utilization by the brain. Our finding of normal concentrations of total serum B12 in multiple sclerosis confirms the reports of Grann and Glass (1961) andWorm-Petersen (1962) . Simpson (1964) (Matthews 1961; , and it is possible that the serum B12 value obtained in the absence of cyanide represents serum cyanocobalamin while the additional B12 obtained in the presence of cyanide represents serum hydroxocobalamin. This hypothesis, which has recently received some further experimental support (Anderson, 1964) , is energetically advocated by Smith (1961) who claims that patients with tobacco amblyopia have an abnormally low proportion of hydroxocobalamin in the blood. Interpreted in this way, the present results would indicate that in multiple sclerosis the blood tends to contain less hydroxocobalamin and more cyanocobalamin than normal. Unfortunately, it is not yet possible to interpret the results with certainty, as the forms in which B12 exists in the blood are unknown. If the bulk of it is in the coenzyme form, the value obtained in the absence of cyanide may reflect not the concentration of cyanocobalamin in the blood but the concentration of cyanide or thiocyanate. However, the finding of the difference that has been described between patients with multiple sclerosis and control subjects indicates the desirability of further investigation.
Though B12 is often given in multiple sclerosis, there is little to suggest that it influences the course of the disease (Simpson, 1964) , and the present work has produced no evidence of overt B12 deficiency in the condition. If the vitamin is to be given, there is a case for using hydroxocobalamin, which is retained in the body longer than cyanocobalamin. The present results might be regarded as additional justification for preferring hydroxocobalamin to the cyano-form.
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